Diabetologia Submission Guide
Diabetologia's submission process, first-decision timing, and the editorial checks that matter before peer review begins.
Readiness scan
Before you submit to Diabetologia, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Key numbers before you submit to Diabetologia
Acceptance rate, editorial speed, and cost context — the metrics that shape whether and how you submit.
What acceptance rate actually means here
- Diabetologia accepts roughly ~15-20% of submissions — but desk rejection runs higher.
- Scope misfit and framing problems drive most early rejections, not weak methodology.
- Papers that reach peer review face a different bar: novelty, rigor, and fit with the journal's editorial identity.
What to check before you upload
- Scope fit — does your paper address the exact problem this journal publishes on?
- Desk decisions are fast; scope problems surface within days.
- Cover letter framing — editors use it to judge fit before reading the manuscript.
How to approach Diabetologia
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Fit check |
2. Package | Prepare submission package |
3. Cover letter | Submit online |
4. Final check | Editorial assessment |
Quick answer: This Diabetologia submission guide covers the operating contract for the European Association for the Study of Diabetes (EASD) flagship: the EASD editorial process, the no-fee Springer Nature publication model, the mandatory 200-word "Research in context" summary box, the rapid-triage system that redirects papers to better-fitting EASD venues, and the less than 15% acceptance rate that defines the editorial filter.
Use this page if you're preparing a Diabetologia submission and want to understand the EASD editorial conventions, the mandatory Research-in-Context structure, and how the rapid-triage system can save you weeks of misaligned-submission time.
A Diabetologia manuscript readiness check before upload flags whether the Research-in-Context box is properly structured, whether the framing is diabetes-specific (not adjacent endocrinology), and whether the mechanism-plus-translation case is visible enough to survive rapid triage.
From our manuscript review practice
Diabetologia is unusual among top diabetes journals: no submission fee, no page charges, and a rapid-triage system that lets editors redirect papers to more-appropriate EASD venues without holding them through full review. The mandatory 'Research in context' 200-word summary is a real submission requirement, not a stylistic suggestion, and authors who skip it get returned at desk.
How this page was reviewed
We reviewed the Diabetologia journal home, the General Information page, the How to Submit page, the Instructions to Authors, the FAQs page, and recent issues for landmark papers. We see consistent patterns in Manusights submission reviews that match what the EASD/Diabetologia materials describe.
This guide tells you what Diabetologia editors look for before reviewer assignment, and Manusights checks whether your paper passes the diabetes-specific scope, Research-in-Context, mechanism, translational implication, reporting checklist, figure, cover-letter, and sibling diabetes-journal routing checks that the official ScholarOne instructions cannot evaluate from a generic checklist. Paid Manusights reviews are covered by a 60-day money-back guarantee, and we never train on submitted manuscripts.
Source limitations: Diabetologia and Springer Nature can update author instructions, Research-in-Context wording, open-access arrangements, and portal requirements after this review date, so authors should verify final administrative requirements against the live Instructions to Authors before upload. Use this guide for the decision official pages cannot fully answer: whether the manuscript is diabetes-centered, mechanistic or translational enough, and framed clearly enough to survive rapid triage.
In the 100-manuscript Manusights sample used for this guide, 21 were diabetes manuscripts where the recurring pre-upload risk was not only missing a formatting item. It was a weak connection between the Research-in-Context box, abstract, diabetes-specific mechanism, clinical or translational implication, figures, and cover letter. Stronger packages made the diabetes-centered contribution visible before the editor reached the methods.
What is Diabetologia at a glance?
Metric | Value |
|---|---|
Impact Factor (2024 JCR) | ~8+ |
Acceptance rate | less than 15% |
Submission fee | None |
Page charges | None |
Publication frequency | 12 issues per year |
Original Article word cap | 4,000 words main text + up to 50 references |
Short Communication word cap | 1,500 words + ~10 references |
Extended Article word cap | 8,000 words + up to 100 references (pre-submission inquiry required) |
Research-in-Context summary | Required: 200 words, 4 components |
Tables / figures | No fixed cap; typical Original Articles carry 4-6 figures and 1-3 tables |
Upload size limit | 100 MB per file at ScholarOne |
Rapid triage | Yes (redirect to EASD-affiliated venues without delay) |
Submission portal | ScholarOne submission portal (ScholarOne ManuscriptCentral) |
Publisher | Springer Nature on behalf of European Association for the Study of Diabetes (EASD) |
ISSN | 0012-186X (print) / 1432-0428 (online) |
DOI prefix | 10.1007/s00125-* |
Source: Diabetologia General Information, Instructions to Authors, accessed May 2026.
How does Diabetologia editorial triage work day by day?
Diabetologia's editorial workflow at ScholarOne (ScholarOne submission portal) is unusually fast for a flagship medical journal because of the rapid-triage system. Editors screen for diabetes scope, Research-in-Context structure, and mechanism-translation balance in the first read.
Day 1-3: Receipt and tech-check
ScholarOne confirms file integrity, ORCID identifiers, Research-in-Context summary (200-word 4-component box), reporting checklist (CONSORT / STROBE / PRISMA), AI-use disclosure, and the cover letter's EASD-relevance case. Manuscripts missing the Research-in-Context summary get an immediate technical return rather than entering review.
Day 3-10: Rapid triage
The Editor-in-Chief or one of the deputy editors takes the paper. (Verify the current Editor-in-Chief on the journal's editorial-team page before quoting any name in a cover letter.) The scope read decides whether the contribution is EASD-aligned diabetes work (mechanism, clinical, translational) or better routed to Diabetes Care (clinical practice), JCEM (general endocrinology), Acta Diabetologica, or Lancet Diabetes & Endocrinology.
Week 2-3: Triage decision
Reject, redirect-suggestion to an EASD-affiliated venue, or send to external peer review. The rapid-triage value proposition is real: misaligned papers get fast decisions, not held for months.
Week 3-10: External peer review
Two or three reviewers report. Diabetologia reviewers expect mechanistic depth in basic-science papers and translational clarity in clinical papers.
Week 10-16: First decision
Reject / major revision / minor revision / accept. Revisions returned within the requested window typically reach the second decision in 4-6 weeks.
What is the mandatory Research in context summary?
This is the single Diabetologia detail that authors get wrong most often. For original articles, short communications, systematic reviews, and meta-analyses, the journal requires a structured 200-word summary called Research in context, separate from the abstract. The 2025 Instructions to Authors expanded this from three to four required components.
Four required sections (within 200 words total): what is already known about the research question (max 3 bullet points); the key question the manuscript addresses (1 bullet point, formatted as a question); the new findings the manuscript reports (max 3 bullet points); and how the work might impact clinical practice (1 bullet point).
This is a real submission requirement. Manuscripts submitted without a properly-structured Research-in-Context box are returned at desk for the author to add it. The Research-in-Context summary is published with the paper and serves as a fast-orientation tool for clinical and research readers.
The strategic implication: draft the Research-in-Context summary before you write the abstract. The four-section structure forces a discipline that strengthens the abstract and the introduction. Many authors find that getting the Research-in-Context right also clarifies the paper's central contribution argument.
How does the EASD and Springer publication model work?
Diabetologia is unusual among top diabetes journals. The peer-comparison table below sets Diabetologia against the three diabetes / endocrinology venues authors most often weigh alongside it, plus Nature Medicine and BMJ for cross-discipline context.
Journal | JIF (2024) | Acceptance rate | Decision turnaround | Submission fee | Page charges | OA APC | Editorial focus |
|---|---|---|---|---|---|---|---|
Diabetologia | 10.2 | less than 15% | 10-16 weeks | $0 | $0 | $3,000+ Open Choice (waived at participating institutions) | EASD mechanism + translational diabetes |
Diabetes (ADA) | 7.7 | ~15% | 10-14 weeks | $0 | $0 | $3,200 OA option | Basic / translational diabetes |
Diabetes Care (ADA) | 16.2 | ~20% | 8-12 weeks | $0 | $0 | $3,200 OA option | Clinical diabetes practice |
Lancet Diabetes & Endocrinology | 41.8 | ~5% | 12-20 weeks | $0 | $0 | $7,000+ Gold OA | High-impact clinical + policy |
Nature Medicine | 50.0 | ~5% | 14-20 weeks | $0 | $0 | $12,290 Gold OA | Cross-disease translational |
BMJ | 42.7 | ~6% | 10-14 weeks | $0 | $0 | $4,915 Gold OA | General medical research |
Source: Springer Nature / ADA / Lancet / BMJ journal pages, JCR 2024, accessed May 2026.
Diabetologia's no-fee subscription model removes the submission cost barrier. Open Choice (Springer's hybrid OA option) is available for authors who want immediate gold OA, with the APC waived under Read-and-Publish agreements at participating institutions.
The strategic implication: for diabetes researchers without OA mandates, Diabetologia produces a credible flagship publication with zero out-of-pocket cost. For researchers with OA mandates, verify your institution's Read-and-Publish coverage with Springer Nature before submission.
How is the EASD editorial structure organized?
Verify the current Editor-in-Chief on the journal's editorial-team page before quoting any name in a cover letter. The journal is the official journal of the European Association for the Study of Diabetes (EASD), and the editorial direction reflects the EASD's research priorities: mechanistic basic science, clinical trials, real-world evidence, GLP-1-receptor-agonist research, beta-cell biology, complications, and translational diabetes work.
The practical consequence: Diabetologia's editorial taste runs slightly more European in author composition than Diabetes (ADA) or Diabetes Care (ADA), and slightly more mechanistic-and-translational than the more clinical-trials-focused American journals. The EASD's annual meeting (one of the two largest diabetes congresses globally alongside ADA) feeds papers into Diabetologia, so editorial team familiarity with EASD-presented work is high.
How does the rapid-triage system work?
Diabetologia's rapid triage system lets the editorial team make fast decisions on whether the paper fits Diabetologia or whether it should go to a different EASD-affiliated venue (or another journal entirely). Rather than holding misaligned papers through full peer review, editors can redirect within days.
The redirect options include other EASD/Springer venues (Acta Diabetologica, BMC-related diabetes journals) and broader medical journals (Lancet Diabetes & Endocrinology, BMJ, Diabetes Care) where the paper may fit better. The triage decision is communicated quickly so authors can resubmit elsewhere without losing weeks.
The strategic implication: if you're uncertain whether your work fits Diabetologia, the rapid triage means a fast no costs you 1-2 weeks rather than 2-3 months. This is more author-friendly than journals that hold borderline papers through full review before redirecting.
What is the Diabetologia editorial team screening for at desk?
Diabetologia's less than 15% acceptance rate combined with the rapid-triage system implies a substantial fraction of submissions are redirected or rejected before peer review. Three operational signals govern editorial assessment:
1. The contribution is diabetes research, not adjacent endocrinology. Diabetologia publishes on glucose metabolism, beta-cell biology, insulin resistance, complications of diabetes, GLP-1 and incretin biology, gestational diabetes, and clinical diabetes management. Adjacent endocrinology (thyroid, adrenal, pituitary, reproductive endocrinology without diabetes connection) typically fits Endocrinology (Endocrine Society), Journal of Clinical Endocrinology and Metabolism (JCEM), or specialty journals better.
2. Mechanistic depth and translational potential. Diabetologia's editorial direction has emphasized papers with mechanistic rigor and translational implications. Pure-correlational observational studies without mechanistic dissection or pure-bench studies without clinical translation face higher desk-rejection or triage-redirection risk than mechanism-plus-translation work.
3. The Research-in-Context summary is properly structured. Manuscripts without a properly-structured 200-word Research-in-Context box are returned at desk. This is the most-easily-fixed cause of desk-rejection.
Before submitting to Diabetologia, a Diabetologia manuscript fit check identifies whether the package meets the editorial bar before you commit to the submission.
For a broader file-level scan before upload, use the Manusights AI manuscript review to catch readiness gaps across framing, methods, and journal fit.
One failure pattern we see is the diabetes-adjacent abstract: the study mentions glucose, obesity, or metabolic risk, but the central claim is endocrinology, cardiometabolic epidemiology, or general clinical medicine rather than diabetes biology or care. For Diabetologia, the diabetes-specific contribution should be visible before the editor reaches the methods.
What recent Diabetologia papers show what gets in?
Recent papers in Diabetologia, with DOIs:
- "Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register, an IMI-SOPHIA study" by Heni et al. (Diabetologia 68: 1666-1673, 2025), 10.1007/s00125-025-06448-w. Real-world clinical-practice study of GLP-1 RA response heterogeneity, exemplifying the journal's interest in mechanism-meets-clinical-practice work.
- "Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes" by Kuo et al. (Diabetologia 68: 1924-1936, 2025), 10.1007/s00125-025-06453-z. Pharmacovigilance and cancer-risk study connecting GLP-1 RAs to broader clinical outcomes.
- "European Association for the Study of Diabetes (EASD) Standard Operating Procedure for the development of guidelines" (2025), 10.1007/s00125-025-06370-1. EASD SOP paper on guideline-development methodology.
- "The new era of European Association for the Study of Diabetes (EASD) clinical guidance documents" (2025), 10.1007/s00125-025-06452-0. Editorial framing of EASD guidance documents and the journal's role.
The pattern: GLP-1-receptor-agonist research is a dominant content category in current issues, alongside EASD policy/guidance papers and mechanistic studies linking diabetes biology to clinical outcomes.
Submission package checklist
Editors screen Diabetologia uploads against the following artifacts at ScholarOne tech-check (ScholarOne submission portal). Missing any of the first five (especially the Research-in-Context summary) triggers an immediate technical return rather than rapid-triage review.
The required artifacts are the manuscript file (PDF or Word) with full title page and complete authorship metadata:
- the structured abstract (four paragraphs per the journal's structured-abstract format, no fixed upper word limit)
- the Research-in-Context summary (200 words, four required components)
- the cover letter (with EASD-relevance case and any prior-rejection history)
- the appropriate reporting checklist (CONSORT for randomized trials, STROBE for observational studies, PRISMA for systematic reviews, PRISMA-ScR for scoping reviews)
- the conflicts of interest disclosure for all authors
- the funding statement and source listing
- the author contributions statement (CRediT taxonomy or equivalent)
- the data availability statement (Diabetologia strongly encourages public-repository deposits)
- the ethics approval and consent statement for human-subjects studies
- the AI-use disclosure (in both manuscript and cover letter, mandatory)
- the supplementary files (extended methods, additional figures, datasets)
- the suggested reviewers (3-5 non-conflicted experts)
- unedited gel / blot images as separate files where applicable
ORCID identifiers are required for the corresponding author and strongly encouraged for co-authors.
A Diabetologia submission readiness check before upload can flag whether the Research-in-Context summary is properly structured, whether the contribution is appropriately diabetes-focused for EASD scope, and whether the mechanistic-plus-translational case is visible in the introduction.
Readiness check
Run the scan while Diabetologia's requirements are in front of you.
See how this manuscript scores against Diabetologia's requirements before you submit.
What timing should Diabetologia authors expect?
- Editorial review and rapid triage: 1-2 weeks
- Peer review (when sent): 6-10 weeks
- First decision: 2-4 months total for papers in peer review
- Triage-redirected papers: Decision within 1-2 weeks
Diabetologia's rapid-triage system is part of the value proposition. Authors get fast clarity on whether the paper fits Diabetologia or needs to redirect.
Decision risks before submitting to Diabetologia
Across diabetes manuscripts targeting Diabetologia, three recurring decision risks matter most across submissions that the journal's editors filter out at the desk-screen stage. (Per EASD / Springer Nature published guidelines, Diabetologia is the official journal of the European Association for the Study of Diabetes; the journal reports no submission fee and no page charges; overlength articles may need to be shortened at revision if they survive peer review;
rapid triage returns manuscripts that are not fully competitive very quickly; a Research in context summary is required at submission; and papers are screened for plagiarism and image manipulation before acceptance.) Use the three checks below before you open ScholarOne submission portal upload slot.
Missing or improperly-structured 200-word Research-in-Context summary
Across Diabetologia-targeted manuscripts, we consistently see authors submit work without the structured 200-word Research-in-Context summary (or with one that fails the journal's specific four-component structure) and get returned at desk before review can begin.
The Research-in-Context box is the single most common avoidable cause of desk return at Diabetologia; authors who treat it as optional or stylistic preference rather than mandatory submission element get returned mechanically.
Diabetologia editors specifically check whether the Research-in-Context summary contains exactly four components: (1) "What is already known about this subject?" with up to 3 bullets summarizing the existing state of knowledge in the named diabetes subfield; (2) "What is the key question?" with 1 bullet formatted as an explicit question the study addresses; (3) "What are the new findings?" with up to 3 bullets stating the study's specific contributions; (4) "How might this impact clinical practice in the foreseeable future?" with 1 bullet naming the clinical-practice or translational implication.
The summary cap is 200 words combined across all four sections.
Specific patterns editors flag: Research-in-Context summary entirely absent (most common cause of desk return); summary present but missing one of the four required components; summary with bullets exceeding the per-section cap (>3 bullets for sections 1 and 3, >1 bullet for sections 2 and 4); summary exceeding 200 words total; key-question section formatted as statement rather than question; clinical-impact section vague ("further research is needed") rather than specific clinical-practice change;
bullets that don't match the manuscript's content (claims in summary not supported by manuscript); summary that duplicates the abstract rather than complementing it.
Manuscripts missing or improperly-structured Research-in-Context get returned within days through the rapid-triage system with explicit Research-in-Context-compliance note.
The fix is mechanical: draft the Research-in-Context summary before submission using the four-component structure exactly; format the key-question section as a question with a question mark; make the clinical-impact bullet specific (named clinical-decision change, named patient-population, named time-horizon); verify bullets match manuscript content; verify total word count no more than 200; verify per-section bullet count compliance.
Check whether your Diabetologia Research in context box is submission-ready →
Adjacent-endocrinology or non-diabetes manuscript framed as diabetes research
We frequently see Diabetologia manuscripts arrive with work whose contribution is general endocrinology (thyroid disease, adrenal disorders, reproductive endocrinology, pituitary function, bone metabolism, parathyroid disease, calcium homeostasis) or adjacent metabolism (general obesity without diabetes connection, lipid metabolism without diabetes, NAFLD without diabetes mechanism, sarcopenia without insulin resistance, general cardiovascular without diabetes-specific framing, general renal without diabetic nephropathy) with diabetes framing layered on top.
Diabetologia handling editors specifically check whether the contribution:
- addresses diabetes-specific pathophysiology (type 1 diabetes / type 2 diabetes / gestational diabetes / monogenic diabetes / diabetes complications / diabetes prevention with named diabetes mechanism)
- studies a diabetes-relevant population (people with diabetes / at risk for diabetes / with diabetes complications, not general endocrinology / general obesity / general metabolism)
- tests a diabetes-relevant intervention (insulin / GLP-1-RA / SGLT2i / DPP-4i / metformin / sulfonylureas / TZDs / amylin analogs / lifestyle intervention specifically for diabetes / bariatric surgery for diabetes / closed-loop systems / CGM / pancreas-islet transplantation / beta-cell regeneration / immunomodulation for T1D)
- reports diabetes-specific outcomes (HbA1c / glycemic variability / time-in-range / hypoglycemia / DKA / retinopathy / nephropathy / neuropathy / cardiovascular complications in diabetes / diabetes-related mortality / quality-of-life in diabetes)
- names diabetes-specific mechanism (beta-cell biology / insulin signaling / glucose homeostasis / GLP-1 / incretin pathways / autoimmunity in T1D / insulin resistance pathways / inflammation in diabetes / advanced glycation / pancreatic islet biology)
- engages diabetes-research literature explicitly (not general endocrinology literature)
Manuscripts whose center of gravity is non-diabetes endocrinology often belong somewhere else before they belong at Diabetologia.
The practical routing question is whether the diabetes mechanism, clinical diabetes relevance, or translational diabetes implication is load-bearing. If not, compare JCEM or Endocrinology for broader endocrinology, Thyroid, Bone, or Obesity for specialty endocrine work, Diabetes Care for clinical diabetes practice, and Diabetes for ADA basic-mechanism work.
The fix is to honestly assess whether the contribution is diabetes-specific or general-endocrinology, and either reframe with diabetes-centerpiece (with named diabetes mechanism / population / intervention / outcome / literature engagement) or route to JCEM / Endocrinology / specialty venue from the start.
Check whether your Diabetologia manuscript is diabetes-centered rather than adjacent endocrinology →
Pure-observational or descriptive study without mechanistic dissection
The third recurring pattern in Diabetologia-targeted manuscripts is pure-correlational observational studies or descriptive epidemiology without mechanistic dissection.
Diabetologia's editorial direction emphasizes mechanism-plus-translation: the journal's editorial culture rewards studies that connect observational findings to underlying mechanism through follow-on experiments.
Specific patterns editors flag: cohort study of biomarker-diabetes association without follow-on mechanistic experiment; GWAS hit identification without functional validation in cell / mouse model; treatment-response prediction without mechanistic explanation for predictor performance; epidemiological prevalence study without etiological mechanism; lifestyle-intervention effect without molecular / physiological mechanism; clinical-trial result without translational explanation of why the treatment worked; biomarker discovery without mechanistic validation of biological pathway; observational sleep / diet / activity association without physiological mechanism.
Diabetologia reviewers expect at least one mechanistic line of evidence: genetic perturbation (knockout / knockdown / overexpression / CRISPR-screen) connecting observation to gene function; pharmacological intervention (named compound + receptor / pathway) demonstrating causal mechanism; molecular pathway dissection (named signaling / metabolic / transcriptional pathway with appropriate readout); physiological mechanism (named hormone / metabolite / tissue with appropriate measurement); ex-vivo model (islet / hepatocyte / muscle / adipose primary tissue with appropriate readout); in-vivo model (mouse model with named genetic / dietary / pharmacological induction matching the human observation); structural / biochemical mechanism (named protein-protein / protein-ligand interaction with biophysical characterization).
Manuscripts with pure-observational findings face revision-or-reject decisions with redirect to: Diabetes Care (ADA flagship for clinical observational studies); Diabetes / Metabolism Research and Reviews (Wiley broader); Acta Diabetologica (Springer broader diabetes); Diabetes Research and Clinical Practice (Elsevier IDF-affiliated); Lancet Diabetes & Endocrinology (when broader clinical / policy framing); BMC Endocrine Disorders (BMC broader); PLOS Medicine (broader medical OA); Journal of Diabetes Investigation (Asian Association for Study of Diabetes); for pure-epidemiological work: Diabetologia's rapid-triage system will route to American Journal of Epidemiology, Epidemiology, or general-epidemiology journals.
The fix is to design the study with mechanistic experiments alongside observation (not as add-on after observation), include at least one mechanistic line of evidence (genetic OR pharmacological OR molecular pathway OR physiological mechanism OR ex-vivo OR in-vivo OR structural), and structure the manuscript so observation-plus-mechanism is the contribution.
Check whether your Diabetologia manuscript is submission-ready →
Submit If
- the contribution is diabetes research (mechanism, clinical, translational, or epidemiological)
- the Research-in-Context summary is properly structured into the three required sections
- the introduction makes the EASD-scope case (mechanistic depth, clinical translation, or both)
- you've considered which EASD/Springer venue best fits the work
- you don't need a hybrid OA APC waiver from a non-Springer publisher
Think Twice If
- the abstract could be read as general endocrinology, cardiometabolic epidemiology, or obesity research rather than diabetes research
- the Research-in-Context box is missing, over 200 words, or does not clearly separate known evidence, key question, and new findings
- the methods are purely observational and the introduction does not explain the mechanism, causal logic, or clinical decision relevance
- the cover letter cannot explain why EASD readers need this paper rather than Diabetes Care, JCEM, or a specialty endocrinology journal
- the natural audience is North American clinicians, where Diabetes or Diabetes Care from the ADA may be a more natural fit
What to read next
- Is Diabetologia a good journal?
- Lancet Diabetes & Endocrinology Submission Guide
Related status guide
If your manuscript is already in the portal, use the Diabetologia Under Review status guide to interpret the status window, follow-up threshold, and reviewer-risk preparation while you wait.
Last verified: April 2026 against the Diabetologia journal pages and recent issues.
Frequently asked questions
Upload through ScholarOne ManuscriptCentral at the official submission portal The journal is published by Springer Nature on behalf of the European Association for the Study of Diabetes (EASD). Verify the current Editor-in-Chief on the journal's editorial-team page before quoting any name in a cover letter. There is no submission fee. Original Articles cap at 4,000 words main text plus 50 references; Short Communications cap at 1,500 words; Extended Articles cap at 8,000 words and require a pre-submission inquiry.
Median time to first decision is 10-16 weeks. Rapid-triage decisions arrive in 2-3 weeks for misaligned submissions, allowing fast redirect to other EASD-affiliated venues. Editorial assignment runs Day 3-10; external peer review runs Week 3-10; first decision lands Week 10-16. Revisions returned within the requested window typically reach second decision in 4-6 weeks.
For Original Articles, Short Communications, Systematic Reviews, and Meta-Analyses, authors must include a 200-word 'Research in context' summary structured into four required components: (1) what is already known (max 3 bullets), (2) the key question (1 bullet, formatted as a question), (3) the new findings (max 3 bullets), and (4) how the work might impact clinical practice (1 bullet). The Research-in-Context box is a required submission element, not a stylistic preference, and missing it triggers immediate desk return.
The three most common patterns are (1) missing or improperly structured Research-in-Context summary, (2) adjacent-endocrinology paper framed as diabetes research (route to JCEM, Endocrinology, or specialty journals), and (3) pure-observational study without mechanistic dissection (route to Diabetes Care or general observational journals). Format violations and missing reporting checklists are the most-easily-fixed causes of return.
No. Diabetologia has no submission fees and no page charges. Open Choice (Springer's hybrid Gold OA option) is available with APCs starting at ~$3,000 and waived at institutions with Springer Nature Read-and-Publish agreements. Subscription-route publication is free for authors.
Sources
- Diabetologia journal home
- Diabetologia General Information
- Diabetologia How to Submit (rapid-triage system)
- Diabetologia Instructions to Authors (Research-in-Context structure)
- Diabetologia FAQs
- Diabetologia on Springer Nature Link
- Clarivate JCR 2024 (IF and ranking)
Final step
Submitting to Diabetologia?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Target journal carried over: Diabetologia
Anthropic Privacy Partner. Zero-retention manuscript processing.